Detected ·
Claris Biotherapeutics
$118M—
Claris Biotherapeutics closed a $118M Series B financing to advance its lead candidate toward pivotal studies in limbal stem cell deficiency (LSCD), a blinding disease with no approved drug therapy. Key leadership appointments include Stephen Brady as President & CEO, Brian Baum as Chief Commercial Officer, and Marc de Garidel as Chairman of the Board.
- Website
- clarisbio.com
- linkedin.com/company/claris-bio
- Amount
- $118 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-07-29 08:12:55 UTC
- Signal ID
- eb44db7c-1d0e-480a-b60a-39f82e4c2342
As the API returns it
{
"id": "eb44db7c-1d0e-480a-b60a-39f82e4c2342",
"created_at": "2026-07-29T08:12:55.338022Z",
"company_name": "Claris Biotherapeutics",
"company_website_url": "clarisbio.com",
"company_linkedin_url": "https://www.linkedin.com/company/claris-bio",
"event_type": "funding",
"funding_amount": 118000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Claris Biotherapeutics closed a $118M Series B financing to advance its lead candidate toward pivotal studies in limbal stem cell deficiency (LSCD), a blinding disease with no approved drug therapy. Key leadership appointments include Stephen Brady as President & CEO, Brian Baum as Chief Commercial Officer, and Marc de Garidel as Chairman of the Board.*"
}